| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
Ridinilodium is a novel family of antibacterial medications that doesn't seem to work via the traditional antibiotic action channels, like blocking the creation of proteins, lipids, cell walls, RNA, or DNA. Cell division may be hampered by rediprazole. Ridinilodium has long-lasting post-antibiotic effects and is bactericidal against Clostridium difficile. When 82 clinical isolates of C. difficile, including ribotype 027, were subjected to susceptibility testing, rindinilmaze showed strong growth inhibition with a low minimum inhibitory concentration (MIC) of 0.06-0.25 µg/mL. This is lower than the MICs of metronidazole (MIC range: 0.125-8 µg/mL; MIC90, 8 µg/mL) and vancomycin (MIC range: 0.5-4 µg/mL; MIC90, 2 μg/ml) combined. Similarly, it was discovered that rindinilmaze was superior to vancomycin or metronidazole in terms of stopping the growth of 50 C. difficile strains that were identified by ribotype. With a MIC range of 0.06–0.5 µg/mL and a MIC90 of 0.125 µg/mL, rindinilodium is similarly active against particular C. difficile ribotypes, including ribotypes 001, 002, 005, 014, 027, 054, and 106. Furthermore, Ridinilodium has greater efficacy against 11 ribotype 027 bacteria when compared to metronidazole or vancomycin [1].
|
|---|---|
| ln Vivo |
Vancomycin was less successful than ridinilmaze for treating C strains that were either epidemic or non-epidemic. difficile in a once-daily dosage schedule for CDI in hamsters. As with the twice-daily dosage study, cecal and plasma concentrations of ridinilmaze were significantly above the minimum inhibitory concentration (MIC) and below detection levels, respectively, indicating that the drug is nonabsorbable and causes little systemic exposure [1].
|
| References |
[1]. Vickers RJ, et al. Ridinilazole: a novel therapy for Clostridium difficile infection. Int J Antimicrob Agents. 2016 Aug;48(2):137-43.
|
| Additional Infomation |
Ridinilazole is under investigation in clinical trial NCT02092935 (A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)).
Ridinilazole is a narrow-spectrum antibiotic with potential activity against Clostridioides difficile infection (CDI). Upon oral administration, ridinilazole exerts its bactericidal activity against C. difficile through inhibition of cell division. This suppresses bacterial toxin production and inhibits the associated inflammatory response. Compared to other antibiotics that treat C. difficile, ridinilazole does not deplete intestinal bacteria and preserves the intestinal bacterial activity and the associated bile acid metabolome. |
| Molecular Formula |
C24H16N6
|
|---|---|
| Molecular Weight |
388.434
|
| Exact Mass |
388.143
|
| CAS # |
308362-25-6
|
| PubChem CID |
16659285
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
774.9±70.0 °C at 760 mmHg
|
| Flash Point |
352.4±28.6 °C
|
| Vapour Pressure |
0.0±2.7 mmHg at 25°C
|
| Index of Refraction |
1.764
|
| LogP |
3.51
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
30
|
| Complexity |
524
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
N1([H])C(C2C([H])=C([H])N=C([H])C=2[H])=NC2C([H])=C([H])C(=C([H])C1=2)C1C([H])=C([H])C2=C(C=1[H])N([H])C(C1C([H])=C([H])N=C([H])C=1[H])=N2
|
| InChi Key |
UHQFBTAJFNVZIV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C24H16N6/c1-3-19-21(29-23(27-19)15-5-9-25-10-6-15)13-17(1)18-2-4-20-22(14-18)30-24(28-20)16-7-11-26-12-8-16/h1-14H,(H,27,29)(H,28,30)
|
| Chemical Name |
2-pyridin-4-yl-6-(2-pyridin-4-yl-3H-benzimidazol-5-yl)-1H-benzimidazole
|
| Synonyms |
SMT19969; SMT 19969; SMT-19969
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~64.36 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.44 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5745 mL | 12.8723 mL | 25.7447 mL | |
| 5 mM | 0.5149 mL | 2.5745 mL | 5.1489 mL | |
| 10 mM | 0.2574 mL | 1.2872 mL | 2.5745 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
